Menu

VFT and NEI Partner to Identify Potential Treatments for OCA Patients

Vision for Tomorrow is proud to partner with the National Eye Institute (NEI), a division of the National Institutes of Health (NIH), to fund a study attempting to identify drugs that will improve vision in people with oculocutaneous albinism (OCA). This study is being led by Dr. Brian Brooks of the NEI, a reknowned researcher […]

Feb 22, 2017 / Comments Off on VFT and NEI Partner to Identify Potential Treatments for OCA Patients /
read more

PTC Therapeutics Shares Update on STAR Research

Phase 2 Proof-of-Concept Study for ataluren in Nonsense Mutation Aniridia PTC Therapeutics’ STAR study is a Phase 2 proof-of-concept study of ataluren, an orally administered, first-in-class, protein restoration therapy for the treatment of nonsense mutation aniridia, a rare genetic disorder that results in disruption in the development of the eye. The STAR study is a […]

Dec 04, 2016 / Comments Off on PTC Therapeutics Shares Update on STAR Research /
read more

The Vision for Tomorrow Foundation Announces New Director of Scientific Affairs

The Vision for Tomorrow Foundation is pleased to announce that Dr. Bruce Bloom, President and Chief Science Officer of the non-profit Cures Within Reach, has joined the Vision for Tomorrow team as Director of Scientific Affairs. Dr. Bloom brings more than 30 years of medical research, clinical trial and non-profit management experience to the Foundation. […]

Nov 18, 2016 / Comments Off on The Vision for Tomorrow Foundation Announces New Director of Scientific Affairs /
read more
Showing all 3 results
Copyright 2017 - Vision for Tomorrow - All Rights Reserved.
Designed by Miller Designs, LLC
  TOP